TRADU
8.5.2024 09:01:35 CEST | Business Wire | Press release
Tradu, the powerful multi-asset trading platform, has launched a new crypto exchange with low, transparent fees tailored for active traders and investors seeking a trustworthy and secure platform for their crypto assets. From today, crypto traders can securely invest in over 40 coins including Bitcoin and Ethereum via Tradu’s multi-asset trading platform. Tradu is part of Stratos Group International, LLC (“Stratos”), a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF).
Tradu is taking a fresh approach to crypto, offering a simple and transparent cost structure that saves investors up to 95% of the fees that can be charged in crypto trading. The platform displays commissions and real-time spreads before orders are placed, giving traders full transparency on all transaction costs. Tradu charges just 0.1% commission with instant rebates of 0.02% and 0.05% for larger trade sizes. The commission for a 1 BTC trade (at a price of $60,000) is just $30 at Tradu versus as much as $600 at other exchanges.*
Tradu clients can also choose to trade on a commission-free profile opting to instead add the fee to the spread. Clients can simply click to change between the Zero Commission and the Raw Spreads profile options in the platform. Clients have the flexibility to choose the profile that best suits their trading style.
Other key features include:
Uniform trading fees: Tradu maintains equal fees for maker and taker transactions, promoting fairness, simplicity and transparency in trading.
Free crypto deposits and easy withdrawals: Crypto deposits are free with Tradu while withdrawals are easy and fees are simple and clear.
Comprehensive support: Access customer support through various channels, including email, chat, and phone, ensuring prompt assistance for user queries.
Brendan Callan, CEO of Tradu, commented: “At Tradu, we are real supporters of crypto. It’s a huge market with significant investor interest and as a true multi-asset trading platform, it’s important for us to offer our clients access to both traditional assets and new digital assets. We are bringing institutional-grade pricing and infrastructure to the retail crypto market, providing traders with upfront costs and tight, transparent spreads enabling active traders and investors to maximise their returns. Tradu is focused on creating stable, secure and frictionless cryptocurrency trading through technology, delivering a better, safer and lower cost service. Clients can reach out to our support team for detailed instructions on how to transfer their crypto portfolio over to Tradu.”
In addition to cryptocurrencies, Tradu users can also access over 10,000 trading products across equities, forex and CFDs on commodities, stocks, treasuries and indices all from one powerful portal that can be accessed via a user-friendly mobile app and web platforms.
Visit crypto.tradu.com to sign up and gain access to a wide range of assets**.
Notes to editors
* Costs calculated based on buying one Bitcoin at a price of $60,000. Tradu cost includes a 0.05% rebate based on order size. Comparative pricing based on a standard account type and information from broker websites as of 1st May 2024. It does not reflect the whole market. Actual fees may vary due to factors like account type, rebates, volume, and market conditions.
**Products vary depending on location, visit tradu.com to check which products are available in your region.
About Tradu
Tradu is headquartered in London with offices around the world. The global Tradu team speaks more than two dozen languages and prides itself on its responsive and helpful client support.
Stratos also operates FXCM, an FX and CFD platform founded in 2001. Stratos will continue to offer FXCM services alongside Tradu’s multi-asset platform.
Stratos subsidiaries are authorised and regulated in the UK, Europe, Australia and South Africa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508810010/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom